ImmunityBio Inc - Company Profile

Powered by

All the data and insights you need on ImmunityBio Inc in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date ImmunityBio Inc Strategy Report

  • Understand ImmunityBio Inc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

ImmunityBio Inc: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

ImmunityBio Inc (ImmunityBio), a subsidiary of NantWorks LLC, is a clinical-stage biotechnology company developing therapies for therapies for cancer and infectious diseases. The company product pipeline includes anktiva + BCG, anktiva + keytruda (pembrolizumab), aldox + anktiva + PD-L1 t-hank, anktiva + tri-ad5 vaccines, anktiva + bevacizumab + PD-L1 t-hank, anktiva + IBRX-042 vaccination, anktiva + M-ceNK and anktiva + CD19 t-haNK. ImmunityBio pipeline candidates treat bladder cancer, lung cancer, lynch syndrome, pancreatic cancer, glioblastoma, HPV, advanced Solid tumors, non-hodgkin lymphoma and HIV. The company operates in Italy, South Korea and the US. ImmunityBio is headquartered in San Diego, California, the US.

 Gain a 360-degree view of ImmunityBio Inc and make more informed decisions for your business Gain a 360-degree view of ImmunityBio Inc and make more informed decisions for your business Find out more
Headquarters United States of America
Address 3530 John Hopkins Court, San Diego, California, 92121
Website immunitybio.com
Telephone 1 858 6330300
No of Employees 628
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange IBRX (NASD)
Revenue (2022) $622,000 159.2% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ -40% (2022 vs 2021)
Market Cap* $5.2B
Net Profit Margin (2022) XYZ 46.0% (2022 vs 2021)
* As of and is in US$
View ImmunityBio Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

ImmunityBio Inc premium industry data and analytics

100+

Clinical Trials

Determine ImmunityBio Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

90+

Pipeline Drugs

Identify which of ImmunityBio Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

80+

Catalyst Calendar

Proactively evaluate ImmunityBio Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

40+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for ImmunityBio Inc’s relevant decision makers and contact details.

20+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

8

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

Products and Services

Products Brands
Pipeline Nantkwest
Anktiva + BCG: Bladder Cancer aNK
Anktiva + Keytruda (Pembrolizumab: Lung Cancer haNK
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand ImmunityBio Inc portfolio and identify potential areas for collaboration Understand ImmunityBio Inc portfolio and identify potential areas for collaboration Find out more

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 Contracts/Agreements In May, the company entered into a partnership with the Serum Institute of India for Bacillus Calmette-Guerin.
2023 Others In October, the company completed the resubmission of its Biologics License Application to the U.S. Food and Drug Administration for N-803.
2023 Contracts/Agreements In July, the company entered into a securities purchase agreement for a registered direct offering with multiple institutional investors.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Find out more
Image for loader

Competitor Comparison

Key Parameters ImmunityBio Inc AbbVie Inc Precigen Inc Bellicum Pharmaceuticals Inc Biostax Corp
Headquarters United States of America United States of America United States of America United States of America United States of America
City San Diego North Chicago Germantown Houston Winter Park
State/Province California Illinois Maryland Texas Florida
No. of Employees 628 50,000 202 13 -
Entity Type Public Public Public Private Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Patrick Soon-Shiong Chief Scientific Officer; Chairman; Chief Medical Officer Executive Board 2014 70
Rich Adcock Chief Executive Officer; President; Director Executive Board 2020 54
Barry J. Simon Director; Chief Corporate Affairs Officer Executive Board 2017 58
David Sachs Chief Financial Officer Senior Management 2021 45
Leonard S. Sender Chief Operating Officer Senior Management 2020 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into ImmunityBio Inc key executives to enhance your sales strategy Gain insight into ImmunityBio Inc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer